<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01833377</url>
  </required_header>
  <id_info>
    <org_study_id>NCT12345678</org_study_id>
    <nct_id>NCT01833377</nct_id>
  </id_info>
  <brief_title>Effect of Consumption of Caraway on Treatment of Obesity</brief_title>
  <official_title>Caraway Intake as a Sustainable Dietary Practice: Impact on Overweight &amp; Obese Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Malaya</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Malaya</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the applicability of caraway (black cumin) intake on the&#xD;
      treatment of obesity. So, a randomized placebo controlled clinical trial will be conducted to&#xD;
      examine the applicability of caraway product in terms of safety and efficacy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized placebo-controlled clinical trial, was done on 120 healthy overweight and obese&#xD;
      women aged 20-55 in Iran. data were collected trough questionaires, interview and physical&#xD;
      examination. the required parameters including anthropometric indices, body composition vital&#xD;
      parameters (heart rate and blood pressure)and full blood parameters, were measured before and&#xD;
      after intervention. volunteers were randomized into test and control group and were asked to&#xD;
      consume either caraway samples or placebo during 12 intervention weeks.&#xD;
&#xD;
      the outcome measure will be assessed for both primary and secondary data from baseline&#xD;
      through week 12 (3 months).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in body mass index</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>The changes in BMI from baseline at 12 weeks are measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in all blood parameters</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>The changes in all blood parameters from baseline at 12 weeks are measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in vital parameters (systolic and diastolic blood pressure and pulse rate)</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>The changes in systolic and diastolic blood pressure and pulse rate from baseline at 12 weeks are measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>The changes in body weight from baseline at 12 weeks are measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anthropometric indices including waist, hip, thigh and mid-upper arm circumference (cm)</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>The changes in anthropometric indices including waist, hip, thigh and mid-upper arm circumference from baseline at 12 weeks are measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in appetite</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>The changes in appetite from baseline at 12 weeks are measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body composition including fat percentage, muscle mass, lean body mass, bone mass and water percentage</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>The changes in body composition from baseline at 12 weeks are measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight (kg)</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>The changes in body weight from baseline at 12 weeks are measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in basic and active metabolic rate</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>The changes in BMR and AMR from baseline at 12 weeks are measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in food intake</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in food intake&#xD;
The changes in food intake (macro and micro nutrient intake) from baseline at 12 weeks are measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urine specific gravity</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>The changes in urine specific gravity from baseline at 12 weeks are measured.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Obesity</condition>
  <condition>Overweight</condition>
  <arm_group>
    <arm_group_label>caraway sample</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>caraway sample</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>caraway sample</intervention_name>
    <arm_group_label>caraway sample</arm_group_label>
    <other_name>caraway water extract product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  overweight and obese women (BMI&gt; 25)&#xD;
&#xD;
          -  aged 20-55 years old&#xD;
&#xD;
          -  healthy subjects&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant and lactating women&#xD;
&#xD;
          -  Thyroid disease&#xD;
&#xD;
          -  type I or II diabetes mellitus&#xD;
&#xD;
          -  hypertension (systolic BP 140 and/or diastolic BP 90)&#xD;
&#xD;
          -  endocrine dysfunction&#xD;
&#xD;
          -  impaired liver function&#xD;
&#xD;
          -  chronic renal disease&#xD;
&#xD;
          -  cardiovascular disease&#xD;
&#xD;
          -  primary dyslipidemia&#xD;
&#xD;
          -  myopathy&#xD;
&#xD;
          -  patients using drugs which affect on metabolism or appetite&#xD;
&#xD;
          -  a maintained weight loss in the preceding 3 months&#xD;
&#xD;
          -  meals not eaten at regular intervals&#xD;
&#xD;
          -  participation in another investigation study within the past 30 days&#xD;
&#xD;
          -  a history of alcohol or drug abuse within the past year&#xD;
&#xD;
          -  smoking&#xD;
&#xD;
          -  a history of sleep disorders&#xD;
&#xD;
          -  clinical depression or other psychiatric conditions&#xD;
&#xD;
          -  abnormal obese&#xD;
&#xD;
          -  allergy or sensitivity to any of the 'active' or 'placebo' product ingredients&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>che wan jasimah mohamed radzi, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Malaya</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Majid Hajifaraji, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
  </overall_official>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>March 26, 2013</study_first_submitted>
  <study_first_submitted_qc>April 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2013</study_first_posted>
  <last_update_submitted>April 15, 2013</last_update_submitted>
  <last_update_submitted_qc>April 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>overweight</keyword>
  <keyword>BMI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

